

Assisting Pharmacometric Simulation with the Use of Shiny

Jia Kang, Ph.D.

Senior Scientist I

Metrum Research Group

R/Pharma Conference, August 2018

Acknowledgement

Sponsors

Metrum Team

- Kyle Baron
- John Mondick
- Bill Knebel
- Marc Gastonguay


Pharmacometrics

Development and application of pharmaco-statistical models of drug efficacy and safety from preclinical and clinical data to improve drug development knowledge management and decision-making [1]

[1] Lalonde RL, et.al, Model-based drug development, Clin Pharmacol Ther, 2007

Challenges

- Computation for pharmacometric modeling and simulation can be time-consuming
- Communication
 - Clear communication between pharmacometricians and project team
 - Demonstrate impact of the analysis along with key assumptions for stakeholders
 - Rapid decision making based on current state of knowledge



Shiny

- User-friendly interface
- Interactive presentation
- Real-time computation

Study Design **BE Results** Sensitivity Analysis

Number of study subjects
24

Recruitment of male and female
 Random Fixed

Probability of female [0,1]
0.25

Sampling time points after dosing (hours)
0.5,1,1.5,2,2.083,2.167,2.25,2.33,2.5,2.75,3,3.25,3.5,4,6,10


Formulation effect on
 F Clearance
0.9

Number of trials to be simulated
500

Set simulation seed (a positive integer)
1234

Run Simulation

Typical Concentration-Time Profile to assess sampling times




AUC0_last	AUC0_inf	AUClast/AUCinf
11.16	11.26	0.99

Study Design **BE Results** Sensitivity Analysis

Bioequivalence Criteria
80~125%

Download Study Design and BE results

Success Rate1: percentage of trails where 90% confidence interval of the ratio falls within BE criteria range
Success Rate2: percentage of trials where 90% confidence interval of the ratio falls within BE criteria range AND the point estimate of the ratio falls between 0.8 and 1.25



Each horizontal line represents 90% confidence interval of the estimated ratio of test to reference in AUC;
Green solid line: True formulation difference; Blue solid line: reference line; Blue dash line: BE criteria.

Bioequivalence (BE) trial simulation to evaluate the probability of success based on user-defined study deign

Study Design BE Results Sensitivity Analysis

Study Design BE Results Sensitivity Analysis

Number of study subjects

80

Recruitment of male and female

Random Fixed

Probability of female [0,1]

0.25

Sampling time points after dosing (hours)

0.5,1,1.5,2,2.083,2.167,2.25,2.33,2.5,2.75,3,3.25,3.5,4,6,10

Formulation effect on

F Clearance

0.9

Number of trials to be simulated


500

Set simulation seed (a positive integer)

1234

Run Simulation

Typical Concentration-Time Profile to assess sampling times



AUC0_last	AUC0_inf	AUClast/AUCinf
11.16	11.26	0.99

Bioequivalence Criteria


80~125%

Download Study Design and BE results

Success Rate1: percentage of trails where 90% confidence interval of the ratio falls within BE criteria range

Success Rate2: percentage of trails where 90% confidence interval of the ratio falls within BE criteria range AND the point estimate of the ratio falls between 0.8 and 1.25

BE success rate1: 53.6 %; BE success rate2: 53.6 %



Each horizontal line represents 90% confidence interval of the estimated ratio of test to reference in AUC; Green solid line: True formulation difference; Blue solid line: reference line; Blue dash line: BE criteria.

Bioequivalence (BE) trial simulation to evaluate the probability of success based on user-defined study deign

Drug XYZ simulation to explore the immediate release (IR) formulation and the sustained release (SR) formulation

[Dosing Regimen](#)
[PK profile](#)
[Exposure metrics table](#)
[Simulation Output](#)

IR formulation

SR formulation

Dose (mg)

20

Dose (mg)

40

Duration of release (hour)

12

Run Simulation

Drug XYZ simulation to explore the immediate release (IR) formulation and the sustained release (SR) formulation


[Dosing Regimen](#)
[PK profile](#)
[Exposure metrics table](#)
[Simulation Output](#)

IR formulation

PK profile in days

1 2 3 4 5 6 7 8

Dosing Regimen of Drug XYZ in IR formulation: 20 mg BID




Download IR plot

SR formulation

PK profile in Days

1 2 3 4 5 6 7 8

Dosing Regimen of Drug XYZ in SR formulation: 40 mg in a 12-hr SR QD



Download SR plot

Visualize and compare the exposure between sustained release and immediate release formulations

